Biomedical Engineering Reference
In-Depth Information
42. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko
JJ, et al. (2006) Successful transduction of liver in hemophilia
by AAV-Factor IX and limitations imposed by the host immune
response. Nat. Med. 12(3), 342-347.
43. Fuster MM, Esko JD. (2005). The sweet and sour of cancer:
glycans as novel therapeutic targets. Nat. Rev. Cancer 5(7),
526-542.
44. Gorsi B, Stringer SE. (2007) Tinkering with heparan sulfate
sulfation to steer development. Trends Cell Biol. 17(4),
173-177.
45. Bishop JR, Schuksz M, Esko JD. (2007) Heparan sulphate
proteoglycans fine-tune mammalian physiology. Nature 446
(7139), 1030-1037.
46. Shih PC, Yang MS, Lin SC, Ho Y, Hsiao JC, Wang DR, et al.
(2009) A turn-like structure “KKPE” segment mediates the
specific binding of viral protein A27 to heparin and heparan
sulfate on cell surfaces. J. Biol. Chem. 284(52), 36535-36546.
47. Harada M, Murakami H, Okawa A, Okimoto N, Hiraoka S,
Nakahara T, et al. (2009) FGF9 monomer-dimer equilibrium
regulates extracellular matrix affinity and tissue diffusion. Nat.
Genet. 41(3), 289-298.
48. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL.
(1993) An essential heparin-binding domain in the fibroblast
growth factor receptor kinase. Science 259(5103), 1918-1921.
49. Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA.
(2007). Identification of linear heparin-binding peptides
derived from human respiratory syncytial virus fusion glyco-
protein that inhibit infectivity. J. Virol. 81(1), 261-271.
50. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. (1998)
Glycosaminoglycan-protein interactions: definition of consen-
sus sites in glycosaminoglycan binding proteins. Bioessays
20(2), 156-167.
51. Fromm JR, Hileman RE, Caldwell EE, Weiler JM, Linhardt
RJ. (1995) Differences in the interaction of heparin with
arginine and lysine and the importance of these basic amino
acids in the binding of heparin to acidic fibroblast growth
factor. Arch. Biochem. Biophys. 323(2), 279-287.
52. Heil M, Mitnacht-Krauss R, Issbrucker K, van den Heuvel J,
Dehio C, Schaper W, et al. (2003) An engineered heparin-
binding form of VEGF-E (hbVEGF-E). Biological effects in
vitro and mobilization of precursor cells. Angiogenesis 6(3),
201-211.
53. Delafontaine P, Song YH, Li Y. (2004) Expression, regulation,
and function of IGF-1, IGF-1R, and IGF-1 binding proteins
in blood vessels. Arterioscler. Thromb. Vasc. Biol. 24(3),
435-444.
54. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS,
Radnik BJ, et al. (1994) Adverse effects of recombinant human
insulin-like growth factor I in obese insulin-resistant type II
diabetic patients. Diabetes 43(3), 369-374.
55. Tokunou T, Miller R, Patwari P, Davis ME, Segers VF,
Grodzinsky AJ, et al. (2008) Engineering insulin-like growth
factor-1 for local delivery. FASEB J. 22(6), 1886-1893.
56. Esper RM, Pankonin MS, Loeb JA. (2006) Neuregulins:
versatile growth and differentiation factors in nervous system
development and human disease. Brain Res. Rev. 51(2),
161-175.
57. Buonanno A, Fischbach GD. (2001) Neuregulin and ErbB
receptor signaling pathways in the nervous system. Curr. Opin.
Neurobiol. 11(3), 287-296.
58. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, et al.
(1996). The significance of heregulin in breast cancer tumor
progression and drug resistance. Breast Cancer Res. Treat. 38
(1), 57-66.
59. Mei L, XiongWC. (2008) Neuregulin 1 in neural development,
synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 9(6),
437-452.
60. Falls DL. (2003) Neuregulins: functions, forms, and signaling
strategies. Exp. Cell Res. 284(1), 14-30.
61. Gilmour LM, Macleod KG, McCaig A, Sewell JM, Gullick
WJ, Smyth JF, et al. (2002) Neuregulin expression, function,
and signaling in human ovarian cancer cells. Clin. Cancer Res.
8(12), 3933-3942.
62. Fischbach GD, Rosen KM. (1997) ARIA: a neuromuscular
junction neuregulin. Annu. Rev. Neurosci. 20, 429-458.
63. Yarden Y, Sliwkowski MX. (2001) Untangling the ErbB
signalling network. Nat. Rev. Mol. Cell. Biol. 2(2), 127-137.
64. Loeb JA. (2003) Neuregulin: an activity-dependent synaptic
modulator at the neuromuscular junction. J. Neurocytol. 32(5-
8), 649-664.
65. Li Q, Loeb JA. (2001) Neuregulin-heparan-sulfate proteo-
glycan interactions produce sustained erbB receptor activation
required for the induction of acetylcholine receptors in muscle.
J. Biol. Chem. 276(41), 38068-38075.
66. Loeb J, Fischbach G. (1995) ARIA can be released from
extracellular Matrix through cleavage of a heparin-binding
domain. J. Cell Biol. 130(1), 127-135.
67. Loeb JA, Khurana TS, Robbins JT, Yee AG, Fischbach GD.
(1999) Expression patterns of transmembrane and released
forms of neuregulin during spinal cord and neuromuscular
synapse development. Development 126(4), 781-791.
68. Pankonin MS, Gallagher JT, Loeb JA. (2005) Specific struc-
tural features of heparan sulfate proteoglycans potentiate
Neuregulin-1 signaling. J. Biol. Chem. 280(1), 383-388.
69. Meier T, Masciulli F, Moore C, Schoumacher F, Eppenberger
U, Denzer AJ, et al. (1998) Agrin can mediate acetylcholine
receptor gene expression in muscle by aggregation of muscle-
derived neuregulins. J. Cell Biol. 141(3), 715-726.
70. Montero JC, Rodriguez-Barrueco R, Ocana A, Diaz-Rodriguez
E, Esparis-Ogando A, Pandiella A. (2008) Neuregulins and
cancer. Clin. Cancer Res. 14(11), 3237-3241.
71. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A,
McGuire WL. (1987) Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu
oncogene. Science 235(4785), 177-182.
72. Mendelsohn J, Baselga J. (2000) The EGF receptor family as
targets for cancer therapy. Oncogene 19(56), 6550-6565.
73. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith
DE, et al. (1989) Studies of the HER-2/neu proto-oncogene in
human breast and ovarian cancer. Science 244(4905), 707-712.
Search WWH ::
Custom Search